The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company claims that its Empagliflozin tablets are the most affordable in India
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
U.S. FDA to decide whether to authorize a booster dose in the coming days
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
Equity raise to finance growth and investments in the biological space
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Subscribe To Our Newsletter & Stay Updated
